www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_Morgan_Stanley_Global_Healthcare_Unplugged_Conference_776441 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_Morgan_Stanley_Global_Healthcare_Unplugged_Conference_776441http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_NewsMakers_in_the_Biotech_Industry_Conference_775249 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_NewsMakers_in_the_Biotech_Industry_Conference_775249http://www.finanzen.net/nachricht/Alnylam_Forms_Collaboration_with_Max_Planck_Institute_to_Investigate_Biological_Mechanisms_for_Cellular_Uptake_of_RNAi_Therapeutics_774155Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced it has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, ...http://www.finanzen.net/nachricht/Alnylam_Forms_Collaboration_with_Max_Planck_Institute_to_Investigate_Biological_Mechanisms_for_Cellular_Uptake_of_RNAi_Therapeutics_774155http://www.finanzen.net/nachricht/Alnylam_Pharmaceuticals_Reports_Second_Quarter_2008_Financial_Results_765227Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter of 2008, and company highlights. "RNAi is now broadly recognized as a ...http://www.finanzen.net/nachricht/Alnylam_Pharmaceuticals_Reports_Second_Quarter_2008_Financial_Results_765227http://www.finanzen.net/nachricht/Alnylam_Awarded_Continued_Funding_Under_U_S_Government_Contract_to_Develop_RNAi_Therapeutics_for_Biological_Threats_765215Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has ...http://www.finanzen.net/nachricht/Alnylam_Awarded_Continued_Funding_Under_U_S_Government_Contract_to_Develop_RNAi_Therapeutics_for_Biological_Threats_765215http://www.finanzen.net/nachricht/Alnylam_Withdraws_from_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_763646Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will not be presenting at the Bank of America 2008 Specialty Pharmaceuticals Conference on August 8, 2008, as previously ...http://www.finanzen.net/nachricht/Alnylam_Withdraws_from_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_763646http://www.finanzen.net/nachricht/Alnylam_Consolidates_Intellectual_Property_for_RNA_Activation_RNAa__a_New_Biological_Discovery_for_Activation_of_Gene_Expression_763341Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has consolidated the key intellectual property (IP) for RNA activation (RNAa), creating a dominant IP position in this new ...http://www.finanzen.net/nachricht/Alnylam_Consolidates_Intellectual_Property_for_RNA_Activation_RNAa__a_New_Biological_Discovery_for_Activation_of_Gene_Expression_763341http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_the_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_762975Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview with a focus on delivery and scientific leadership of RNAi therapeutics at the Bank ...http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Presentation_at_the_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_762975http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Conference_Call_Discussing_Second_Quarter_2008_Financial_Results_761306Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter of 2008 on Wednesday, August 6, 2008, after the U.S. financial markets ...http://www.finanzen.net/nachricht/Alnylam_to_Webcast_Conference_Call_Discussing_Second_Quarter_2008_Financial_Results_761306http://www.finanzen.net/nachricht/Alnylam_Grants_New_InterfeRx_TM_Intellectual_Property_License_to_Calando_for_Development_and_Commercialization_of_RNAi_Therapeutics_755954Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has granted Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), a new ...http://www.finanzen.net/nachricht/Alnylam_Grants_New_InterfeRx_TM_Intellectual_Property_License_to_Calando_for_Development_and_Commercialization_of_RNAi_Therapeutics_755954